Back to results
US 6,147,107 AGranted
Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
AssigneeVirginia Commonwealth University
InventorsPaul Dent, Steven Grant, W. David Jarvis
Life of this patent
Estimating the term…
Abstract
Mammaliam cancer cells are effectively killed when treated with a lethal agent (e.g. radiation or chemotherapeutic agents) in combination with an inhibitor specific for the p42/44 MAP kinase cascade "proper".
Claims20
A method for enhancing the killing of cancer cells, comprising the steps of:
- sensitizing said cancer cells by exposing them to an inhibitor that is specific for any step of the p42/44 MAP kinase cascade proper, and
- exposing said cancer cells to a lethal agent selected from the group consisting of taxanes, heat, electrical fields, pH extremes, magnetic fields and radiant energy including ionizing radiation, ultraviolet light and high intensity red light.
A method of treating cancer in mammals, comprising the steps of administering to a patient in need thereof an effective amount of an inhibitor specific for the p42/44 MAP kinase cascade proper, and providing said patient with radiation therapy.
A method of treating cancer in mammals, comprising the steps of
- administering to a patient in need thereof an effective amount of an inhibitor specific for the p42/44 MAP kinase cascade proper, and
- providing said patient with a taxane.
Dependencies are inferred from the claim text.